• Hassaan Ahmed, Kajal Patel, Darren C Greenwood, Stephen Halpin, Penny Lewthwaite, Abayomi Salawu, Lorna Eyre, Andrew Breen, Rory O'Connor, Anthony Jones, and Manoj Sivan.
• School of Medical Sciences, University of Manchester, UK.
• J Rehabil Med. 2020 May 31; 52 (5): jrm00063.

ObjectiveTo determine long-term clinical outcomes in survivors of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus infections after hospitalization or intensive care unit admission.Data SourcesOvid MEDLINE, EMBASE, CINAHL Plus, and PsycINFO were searched.Study SelectionOriginal studies reporting clinical outcomes of adult SARS and MERS survivors 3 months after admission or 2 months after discharge were included.Data ExtractionStudies were graded using the Oxford Centre for Evidence-Based Medicine 2009 Level of Evidence Tool. Meta-analysis was used to derive pooled estimates for prevalence/severity of outcomes up to 6 months after hospital discharge, and beyond 6 months after discharge.Data SynthesisOf 1,169 identified studies, 28 were included in the analysis. Pooled analysis revealed that common complications up to 6 months after discharge were: impaired diffusing capacity for carbon monoxide (prevalence 27%, 95% confidence interval (CI) 15–45%); and reduced exercise capacity (mean 6-min walking distance 461 m, CI 450–473 m). The prevalences of post-traumatic stress disorder (39%, 95% CI 31–47%), depression (33%, 95% CI 20–50%) and anxiety (30%, 95% CI 10–61) beyond 6 months after discharge were considerable. Low scores on Short-Form 36 were identified beyond 6 months after discharge.ConclusionLung function abnormalities, psychological impairment and reduced exercise capacity were common in SARS and MERS survivors. Clinicians should anticipate and investigate similar long-term outcomes in COVID-19 survivors.

41 keywords...

hide…